Photo from wikipedia
Extended‐duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin. We aimed to… Click to show full abstract
Extended‐duration thromboprophylaxis with betrixaban reduces the risk of venous thromboembolism (VTE) without increasing major bleeding rates in acutely ill medical patients as compared to standard duration enoxaparin. We aimed to assess the risk‐benefit of betrixaban in patients aged ≥ 80 years enrolled in the APEX trial.
Keywords:
benefit;
net clinical;
venous thromboembolism;
patients aged;
betrixaban
Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Thrombosis and Haemostasis
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!